Adelaide Ann Hebert

Adelaide Ann Hebert

Auto-generated profile, based on publicly available information

Adelaide Ann Hebert

UTHealth McGovern Medical School Houston Texas USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ESElaine Siegfried
Elaine Siegfried
AHAdelaide A. Hebert
Adelaide A. Hebert
Atopic dermatitis (AD) is one of the most common skin diseases affecting infants and children. A smaller subset of adults has persistent or new-onset AD. AD is characterized by pruritus, erythema, induration, and scale, but these features are also typical of several other conditions that can mimic, coexist with, or complicate AD. These include inflammatory skin conditions, infections, infestations, malignancies, genetic disorders, immunodeficiency disorders, nutritional disorders, graft-versus-host disease, and drug eruptions. Familiarity of the spectrum of these diseases and their distinguishing features is critical for correct and timely diagnosis and optimal treatment.

1 January 2023 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
QNQuoc-Bao D. Nguyen
Quoc-Bao D. Nguyen
MVMai-Anh N. Vu
Mai-Anh N. Vu
AHAdelaide A. Hebert
Adelaide A. Hebert

1 September 2002 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
CWChristy A. Woodruff
Christy A. Woodruff
AHAdelaide A. Hebert
Adelaide A. Hebert

17 January 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
MDMatthew Dallo
Matthew Dallo
KPKavina Patel
Kavina Patel
AHAdelaide A. Hebert
Adelaide A. Hebert
Many indications in dermatology can be effectively managed with topical antibiotics, including acne vulgaris, wound infections, secondarily infected dermatitis, and impetigo. Dermatologists must be familiar with the wide spectrum of topical antibiotics available, including indications, mechanisms of action, adverse events, and spectra of activity. Dermatologists must also keep antibiotic resistance in mind when utilizing these medications. Due to the widespread use of topical antibiotics and their importance in dermatology, a literature review was performed using a systematic search of PubMed and Google Scholar with the terms topical antibiotics, skin infections, dermatology, antimicrobials, and inflammatory dermatoses to identify English-language articles published between 1965–2022 from any country. Relevant publications were manually reviewed for additional content. The following literature review will summarize the common topical antibiotics used in dermatology.

27 October 2016 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
DGDaniel A. Grabell
Daniel A. Grabell
AHAdelaide A. Hebert
Adelaide A. Hebert
Hyperhidrosis is defined as the production of sweat beyond what is physiologically necessary to maintain thermal homeostasis. This disease state may (and typically does) have a significant impact on the patient’s quality of life. Medications including antiperspirants, anticholinergics, and botulinum toxin have been shown to be effective in the management of hyperhidrosis. Several medical device technologies have also proven to be effective. This review article will explore the current and emerging pharmacological and medical device treatments for hyperhidrosis and provide a framework for treating patients who suffer with primary forms of hyperhidrosis.

10 June 2020 in American Journal of Clinical Dermatology
Verified
Journal Article
Open access
PDF file
AHAdelaide A. Hebert
Adelaide A. Hebert
FRFrank Rippke
Frank Rippke
TWTeresa M. Weber
Teresa M. Weber
NNNoreen Heer Nicol
Noreen Heer Nicol
Twice-daily moisturization is recommended by international guidelines as the bedrock of the management of atopic dermatitis (AD). Moisturizers should be selected based on proven clinical effectiveness in improving the skin barrier and improving the symptoms of AD. We searched the PubMed database for clinical trials assessing daily moisturization for the treatment of AD published between 2006 and 2019. Studies had to assess the efficacy of commercially available moisturizers using objective measures of corneometry, transepidermal water loss, or incidence of flare as endpoints, and treatments had to be currently available to patients. Clinical studies showed that moisturization (typically twice daily) significantly improved the skin barrier in adults and children with AD. Longer-term flare studies showed that daily moisturization reduced the incidence of flares and extended the time between flares. Proactive moisturization of infants at high risk of developing AD may reduce its manifestation. Therapeutic moisturizers for AD are specifically formulated with ingredients that target symptoms of AD, such as itch, inflammation, or compromised skin barrier. The US FDA requires that any moisturizer available in the USA and claiming to treat AD must contain colloidal oatmeal. Healthcare providers can maximize compliance and outcomes by educating patients on the benefits of liberally applying a therapeutic moisturizer twice daily to support the skin barrier and help reduce the incidence of flares. Specific recommendations should be for clinically tested moisturizers evaluated using objective, validated skin assessments.